{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:27:08Z","timestamp":1778790428969,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-024-00700-x","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:53:14Z","timestamp":1740469994000},"page":"151-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-9441","authenticated-orcid":false,"given":"Maria Lorenza","family":"Muiesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-0223","authenticated-orcid":false,"given":"Agostino","family":"Virdis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0635-4921","authenticated-orcid":false,"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-2503","authenticated-orcid":false,"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5527-4821","authenticated-orcid":false,"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-9482","authenticated-orcid":false,"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"9438","key":"700_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"key":"700_CR2","unstructured":"Mancia Chairperson G, Kreutz Co-Chair R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023."},{"issue":"34","key":"700_CR3","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"32","key":"700_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease Evidence from genetic, epidemiologic, and clinical studies A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"9976","key":"700_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"9753","key":"700_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"15","key":"700_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"700_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40292-021-00501-6","volume":"29","author":"G Grassi","year":"2022","unstructured":"Grassi G, Del Pinto R, Agabiti Rosei C, Agnoletti D, Borghi C, Cicero AFG, et al. Reduction of high cholesterol levels by a preferably fixed-combination strategy as the first step in the treatment of hypertensive patients with hypercholesterolemia and high\/very high cardiovascular risk: a consensus document by the italian society of hypertension. High Blood Press Cardiovasc Prev. 2022;29(2):105\u201313.","journal-title":"High Blood Press Cardiovasc Prev."},{"key":"700_CR9","doi-asserted-by":"crossref","unstructured":"Members ATF, (CPG) ECfPG, Societies ENC. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"issue":"3","key":"700_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.hjh.0000356766.86388.e5","volume":"27","author":"M Volpe","year":"2009","unstructured":"Volpe M, Tocci G. 2007 ESH\/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens Suppl. 2009;27(3):S3-11.","journal-title":"J Hypertens Suppl"},{"issue":"38","key":"700_CR11","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"key":"700_CR12","unstructured":"Collaboration S-DWGatECR 2023 SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544-56."},{"key":"700_CR13","doi-asserted-by":"crossref","unstructured":"Collaboration SwgaECr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54.","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"700_CR14","doi-asserted-by":"crossref","unstructured":"Collaboration S-OwgaECr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-67.","DOI":"10.1093\/eurheartj\/ehab312"},{"issue":"10","key":"700_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018;72(10):1141\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"700_CR16","unstructured":"Group L-CW. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Eur J Prev Cardiol. 2024."},{"issue":"11","key":"700_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/eurheartj\/ehz239","volume":"41","author":"NEM Jaspers","year":"2020","unstructured":"Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41(11):1190\u20139.","journal-title":"Eur Heart J"},{"issue":"25","key":"700_CR18","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"5","key":"700_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.5603\/CJ.a2022.0087","volume":"29","author":"KJ Filipiak","year":"2022","unstructured":"Filipiak KJ, Babkowski MC, Cameli M, Carugo S, Ferri C, Irisov DB, et al. TIMES TO ACT Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022 Dyslipidemia and arterial hypertension: the two most important and modifiable risk factors in clinical practice. Cardiol J. 2022;29(5):730\u20138.","journal-title":"Cardiol J"},{"issue":"2","key":"700_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40292-021-00503-4","volume":"29","author":"M Volpe","year":"2022","unstructured":"Volpe M, Gallo G, Modena MG, Ferri C, Desideri G, Tocci G, et al. Updated recommendations on cardiovascular prevention in 2022: An executive document of the Italian society of cardiovascular prevention. High Blood Press Cardiovasc Prev. 2022;29(2):91\u2013102.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"6","key":"700_CR21","first-page":"778","volume":"38","author":"DY Lin","year":"2022","unstructured":"Lin DY, Tsai CL, Chang YH, Liang CH, Chuang JY, Chen YH, et al. Real-world data on comparison of lipid-lowering effects between alirocumab and evolocumab in patients with hypercholesterolemia. Acta Cardiol Sin. 2022;38(6):778\u201383.","journal-title":"Acta Cardiol Sin."},{"issue":"16","key":"700_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192\u2013203.","journal-title":"Circulation"},{"issue":"2","key":"700_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"700_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029216","volume":"12","author":"SG Goodman","year":"2023","unstructured":"Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2023;12(18): e029216.","journal-title":"J Am Heart Assoc"},{"key":"700_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","volume":"366","author":"P Gargiulo","year":"2023","unstructured":"Gargiulo P, Basile C, Cesaro A, Marzano F, Buonocore D, Asile G, et al. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis. 2023;366:32\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"700_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","volume":"16","author":"BA Warden","year":"2022","unstructured":"Warden BA, Cardiology BA, Purnell JQ, Duell PB, Fazio S. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022;16(1):94\u2013103.","journal-title":"J Clin Lipidol"},{"issue":"15","key":"700_CR27","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.3390\/ijerph20156496","volume":"20","author":"S Costa","year":"2023","unstructured":"Costa S, Biscaia JL, Horta MR, Romano S, Guerreiro J, Heudtlass P, et al. Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management between Pharmacies and Primary Care in Portugal: a Multicenter Pragmatic Controlled Trial (USFarm\u00e1cia. Int J Environ Res Public Health. 2023;20(15):6496.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"700_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40292-023-00568-3","volume":"30","author":"R Del Pinto","year":"2023","unstructured":"Del Pinto R, Giua C, Keber E, Grippa E, Tilotta M, Ferri C. Impact of 2021 ESC guidelines for cardiovascular disease prevention on hypertensive patients risk: Secondary analysis of save your heart study. High Blood Press Cardiovasc Prev. 2023;30(2):167\u201373.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"5","key":"700_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"700_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"700_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12874-023-02014-3","volume":"23","author":"S Kympouropoulos","year":"2023","unstructured":"Kympouropoulos S. Real World Evidence: methodological issues and opportunities from the European Health Data Space. BMC Med Res Methodol. 2023;23(1):185.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"700_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454\u201363.","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1080\/14656566.2019.1604687","volume":"20","author":"AFG Cicero","year":"2019","unstructured":"Cicero AFG, Landolfo M, Ventura F, Borghi C. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277\u201388.","journal-title":"Expert Opin Pharmacother"},{"key":"700_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99\u2013109.","journal-title":"Atherosclerosis"},{"issue":"11","key":"700_CR35","first-page":"CD12502","volume":"11","author":"S Zhan","year":"2018","unstructured":"Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11(11):CD12502.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"700_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/jcm13040943","volume":"13","author":"N Ferri","year":"2024","unstructured":"Ferri N, Ruscica M, Fazio S, Corsini A. Low-density lipoprotein cholesterol-lowering drugs: A narrative review. J Clin Med. 2024;13(4):943.","journal-title":"J Clin Med"},{"key":"700_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","volume":"288","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Tokg\u00f6zo\u011flu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis. 2019;288:146\u201355.","journal-title":"Atherosclerosis"},{"issue":"7","key":"700_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","volume":"22","author":"AL Catapano","year":"2020","unstructured":"Catapano AL, Pirillo A, Norata GD. New pharmacological approaches to target PCSK9. Curr Atheroscler Rep. 2020;22(7):24.","journal-title":"Curr Atheroscler Rep"},{"issue":"18","key":"700_CR39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"700_CR40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"15","key":"700_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319.","journal-title":"Circulation"},{"issue":"1","key":"700_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-023-01752-4","volume":"22","author":"T Nishikido","year":"2023","unstructured":"Nishikido T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2023;22(1):20.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"700_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","volume":"20","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20(7):791\u2013803.","journal-title":"Expert Opin Pharmacother"},{"key":"700_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","volume":"79","author":"M Banach","year":"2023","unstructured":"Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023;79:2\u201311.","journal-title":"Prog Cardiovasc Dis"},{"key":"700_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"issue":"2","key":"700_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","volume":"17","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Lei L, Ray KK, Ballantyne CM, Bradwin G, Rifai N. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. J Clin Lipidol. 2023;17(2):297\u2013302.","journal-title":"J Clin Lipidol"},{"issue":"18","key":"700_CR47","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"key":"700_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"14","key":"700_CR49","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Magnussen","year":"2023","unstructured":"Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273\u201385.","journal-title":"N Engl J Med"},{"issue":"25","key":"700_CR50","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"700_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.numecd.2016.07.013","volume":"27","author":"C Borghi","year":"2017","unstructured":"Borghi C, Urso R, Cicero AF. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2017;27(2):115\u201320.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"700_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40885-021-00162-6","volume":"27","author":"TH Go","year":"2021","unstructured":"Go TH, Kwak KI, Jang JY, Yu M, Kim HS, Kim JY, et al. Inference of a causal relation between low-density lipoprotein cholesterol and hypertension using mendelian randomization analysis. Clin Hypertens. 2021;27(1):7.","journal-title":"Clin Hypertens"},{"issue":"9","key":"700_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11883-023-01132-z","volume":"25","author":"E D\u0105browska","year":"2023","unstructured":"D\u0105browska E, Narkiewicz K. Hypertension and dyslipidemia: the two partners in endothelium-related crime. Curr Atheroscler Rep. 2023;25(9):605\u201312.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"700_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/HYPERTENSIONAHA.114.04639","volume":"65","author":"M Satoh","year":"2015","unstructured":"Satoh M, Ohkubo T, Asayama K, Murakami Y, Sakurai M, Nakagawa H, et al. Combined effect of blood pressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death: evidence for cardiovascular prevention from observational cohorts in Japan. Hypertension. 2015;65(3):517\u201324.","journal-title":"Hypertension"},{"issue":"1","key":"700_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12872-022-02491-2","volume":"22","author":"C Wang","year":"2022","unstructured":"Wang C, Du Z, Ye N, Shi C, Liu S, Geng D, et al. Hyperlipidemia and hypertension have synergistic interaction on ischemic stroke: insights from a general population survey in China. BMC Cardiovasc Disord. 2022;22(1):47.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"700_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/bmjebm-2017-110888","volume":"23","author":"J Sundstr\u00f6m","year":"2018","unstructured":"Sundstr\u00f6m J, Gulliksson G, Wir\u00e9n M. Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis. BMJ Evid Based Med. 2018;23(2):64\u20139.","journal-title":"BMJ Evid Based Med."},{"issue":"14","key":"700_CR57","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2019.14120","volume":"322","author":"BA Ference","year":"2019","unstructured":"Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. 2019;322(14):1381\u201391.","journal-title":"JAMA"},{"issue":"1","key":"700_CR58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12916-024-03407-x","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Liu H, Shen C, Li J, Liu F, Huang K, et al. Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 \u00d7 2 factorial Mendelian randomization analyses. BMC Med. 2024;22(1):201.","journal-title":"BMC Med"},{"issue":"9364","key":"700_CR59","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet"},{"key":"700_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2022.04.085","volume":"360","author":"MG Mohamed","year":"2022","unstructured":"Mohamed MG, Osman M, Kheiri B, Saleem M, Lacasse A, Alkhouli M. Polypill for cardiovascular disease prevention: systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2022;360:91\u20138.","journal-title":"Int J Cardiol"},{"issue":"10","key":"700_CR61","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/jch.14016","volume":"22","author":"CP Lin","year":"2020","unstructured":"Lin CP, Tung YC, Hsiao FC, Yang CH, Kao YW, Lin YS, et al. Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. J Clin Hypertens (Greenwich). 2020;22(10):1846\u201353.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"700_CR62","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s12325-019-01002-8","volume":"36","author":"A Simon","year":"2019","unstructured":"Simon A, D\u00e9zsi CA. Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL Study. Adv Ther. 2019;36(8):2010\u201320.","journal-title":"Adv Ther"},{"issue":"3","key":"700_CR63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/jch.14645","volume":"25","author":"HT Liu","year":"2023","unstructured":"Liu HT, Deng NH, Wu ZF, Zhou ZY, Tian Z, Liu XY, et al. Statin\u2019s role on blood pressure levels: meta-analysis based on randomized controlled trials. J Clin Hypertens (Greenwich). 2023;25(3):238\u201350.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9435","key":"700_CR64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet"},{"issue":"25","key":"700_CR65","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR66","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/cvr\/cvae136","volume":"120","author":"U Makhmudova","year":"2024","unstructured":"Makhmudova U, Steinhagen-Thiessen E, Volpe M, Landmesser U. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovasc Res. 2024;120(10):1107\u201325.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"700_CR67","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","volume":"191","author":"C Macchi","year":"2021","unstructured":"Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M. Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact. Am J Pathol. 2021;191(8):1385\u201397.","journal-title":"Am J Pathol"},{"issue":"5","key":"700_CR68","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacl.2019.06.006","volume":"13","author":"FJ Raal","year":"2019","unstructured":"Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, et al. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol. 2019;13(5):735\u201343.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"700_CR69","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"700_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030578","author":"A Silla","year":"2023","unstructured":"Silla A, Fogacci F, Punzo A, Hrelia S, Simoni P, Caliceti C, et al. Treatment with PCSK9 inhibitor evolocumab improves vascular oxidative stress and arterial stiffness in hypercholesterolemic patients with high cardiovascular Risk. Antioxidants (Basel). 2023. https:\/\/doi.org\/10.3390\/antiox12030578.","journal-title":"Antioxidants (Basel)"},{"issue":"10","key":"700_CR71","doi-asserted-by":"publisher","first-page":"114269","DOI":"10.1111\/eci.14269","volume":"54","author":"I Cavero-Redondo","year":"2024","unstructured":"Cavero-Redondo I, Moreno-Herraiz N, Del Saz-Lara A, Otero-Luis I, Recio-Rodriguez JI, Saz-Lara A. Effect of adding PCSK9 inhibitors to lipid-lowering interventions on arterial stiffness: a systematic review and meta-analysis. Eur J Clin Invest. 2024;54(10):114269.","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"700_CR72","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.3390\/jcm10112504","volume":"10","author":"E Izkhakov","year":"2021","unstructured":"Izkhakov E, Shacham Y, Serebro M, Yaish I, Marcus Y, Shefer G, et al. The effect of the PCSK9 inhibitor evolocumab on aldosterone secretion among high cardiovascular risk patients: a pilot study. J Clin Med. 2021;10(11):2504.","journal-title":"J Clin Med"},{"issue":"16","key":"700_CR73","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"16","key":"700_CR74","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"key":"700_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100503","volume":"14","author":"W Koenig","year":"2023","unstructured":"Koenig W, Ray KK, Landmesser U, Leiter LA, Schwartz GG, Wright RS, et al. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. Am J Prev Cardiol. 2023;14: 100503.","journal-title":"Am J Prev Cardiol."},{"key":"700_CR76","doi-asserted-by":"publisher","first-page":"1158274","DOI":"10.3389\/fphar.2023.1158274","volume":"14","author":"M Luo","year":"2023","unstructured":"Luo M, Liu Y, Xu X, Liu K, Shen C, Hu H, et al. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1158274.","journal-title":"Front Pharmacol"},{"issue":"8","key":"700_CR77","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","volume":"20","author":"D Schwartz","year":"1967","unstructured":"Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637\u201348.","journal-title":"J Chronic Dis"},{"issue":"5","key":"700_CR78","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jclinepi.2009.01.012","volume":"62","author":"D Schwartz","year":"2009","unstructured":"Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499\u2013505.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"700_CR79","first-page":"1429","volume":"18","author":"M Banach","year":"2022","unstructured":"Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, et al. 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy. Arch Med Sci. 2022;18(6):1429\u201334.","journal-title":"Arch Med Sci"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-024-00700-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:02:50Z","timestamp":1769529770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-024-00700-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s40292-024-00700-x","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised for funding note added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No request to local Ethic Committee has been made, given the descriptive nature of the manuscript (systematic review).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies involving human participants performed by any of the authors. All procedures performed in clinical trials discussed in this manuscript and involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants involved in the clinical trials, according to the study protocols.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}